

26 November 2024

## INOVIQ receives \$1m R&D Tax Incentive Refund

INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to announce that it has received a \$1.018m Research & Development (R&D) Tax Incentive refund relating to its FY24 R&D activities.

The Australian Government's R&D Tax Incentive program provides companies with a 43.5% refundable tax offset for eligible R&D activities. INOVIQ incurred \$2.7m on R&D activities in FY24 and was able to claim the refund on eligible expenditure which excluded certain overseas based expenditure.

*Authorised for release by Company Secretary, Mark Edwards.*

### FURTHER INFORMATION

**Dr Leearne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M +61 400 414 416

**David Williams**  
Chairman  
E [dwilliams@kidder.com.au](mailto:dwilliams@kidder.com.au)  
M +61 414 383 593

### ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit [www.inoviq.com](http://www.inoviq.com).